Clinical trial
Sevicontrol-1: Efficacy and Safety of a Fixed Combination of Olmesartan 40 mg / Amlodipine 10 mg in Patients With Insufficiently Controlled Hypertension Under Monotherapy With Candesartan 32 mg - an Open Phase IIIb Trial
NCT01613209 is registered in ClinicalTrials.gov with Institut für Pharmakologie und Präventive Medizin as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Sevicontrol-1: Efficacy and Safety of a Fixed Combination of Olmesartan 40 mg / Amlodipine 10 mg in Patients With Insufficiently Controlled Hypertension Under Monotherapy With Candesartan 32 mg - an Open Phase IIIb Trial
- Lead sponsor
- Institut für Pharmakologie und Präventive Medizin
- Phase
- Phase 3
- Overall status
- Completed
- Start date
- December 31, 2011
- Completion date
- October 31, 2012
- Enrollment
- 83 (actual)
- Sites
- 12
Conditions
As the registry lists them; a condition with its own page is linked.